Cite
HARVARD Citation
Matasar, M. et al. (2021). Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet oncology. 22 (5), pp. 678-689. [Online].